Jump to ContentJump to Main Navigation

Advances in Medical Sciences

The Journal of Medical University of Bialystok

2 Issues per year

IMPACT FACTOR 2012: 0.796
5-year IMPACT FACTOR: 1.094

Access brought to you by:

provisional account

Open Access
VolumeIssuePage

Open Access

Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy

1 / T Laskus1 / I Bukowska-Ośko1 / A Pawełczyk1 / H Berak2 / A Horban23 / M Fic1 / M Radkowski1

1Department of Immunopathology of Infectious and Parasitic Diseases, Medical University of Warsaw, Poland

2Hospital of Infectious Diseases, Warsaw, Poland

3Clinical Department of Infectious Diseases, Medical University of Warsaw, Poland

This content is open access.

Citation Information: Advances in Medical Sciences. Volume 57, Issue 2, Pages 370–374, ISSN (Online) 1898-4002, ISSN (Print) 1896-1126, DOI: 10.2478/v10039-012-0024-8, January 2013

Publication History

Published Online:
2013-01-29

ABSTRACT

Purpose: Genetic variability of hepatitis C virus (HCV) is considered to be an important factor defining viral pathogenesis, persistence and resistance to treatment. The aim of the present study was to characterize HCV genetic heterogeneity within a hypervariable region 1 (HVR-1) before and during the early period of pegylated interferon alfa (PEG-IFN-α) and ribavirin treatment in correlation with treatment outcome.

Material and Methods: The study involved 24 patients treated with PEG-IFN-α and ribavirin whose sera were collected before (baseline) and at 7, 14, 21 28 and 56 day of treatment. HCV HVR-1 region was amplified by nested RT- PCR and subjected to SSCP (single strand conformational polymorphism) analysis. SSCP changes of HCV HVR-1 over time in each patient were compared to treatment outcome results.

Results: In 2/11 (18%) SVR+ and 8/13 (62%) SVR- treated patients, HVR-1 genetic changes manifested by new SSCP bands (new genetic variants) and were significantly more frequent in nonresponders (P <0.05).

Conclusions: Our results indicate that HCV HVR-1 variability during the early phase of PEG-IFN-α and ribavirin therapy may be predictive of treatment outcome.

Keywords : hepatitis C virus; genetic variation; HVR-1; treatment

  • 1. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr;140(4):1182-8.

  • 2. Clarke DK, Duarte EA, Elena SF, Moya A, Domingo E, Holland J. The red queen reigns in the kingdom of RNA viruses. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4821 4. [CrossRef]

  • 3. Kurbanov F, Tanaka Y, Avazova D, Khan A, Sugauchi F, Kan N, Kurbanova-Khudayberganova D, Khikmatullaeva A, Musabaev E, Mizokami M. Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan. Hepatol Res. 2008 Apr 22;38(5):457-464. [Web of Science]

  • 4. Martell M, Esteban JI, Quer J, Genescà J, Weiner A, Esteban R, Guardia J, Gómez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992 May;66(5):3225-9.

  • 5. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ, Weiner AJ, Bradley DW, Kuo G, Houghton M. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451-5. [CrossRef]

  • 6. Duarte EA, Novella IS, Weaver SC, Domingo E, Wain-Hobson S, Clarke DK, Moya A, Elena SF, de la Torre JC, Holland JJ. RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agents Dis. 1994 Aug;3(4):201-14

  • 7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep;347(13):975-82.

  • 8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar;140(5):346-55. [CrossRef]

  • 9. Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int. 2011 Jan;31 Suppl 1:18-22. [CrossRef]

  • 10. Moraes Coelho HS, Villela-Nogueira CA. Predictors of response to chronic hepatitis C treatment. Ann Hepatol. 2010;9 Suppl:54-60.

  • 11. Navaneethan U, Kemmer N, Neff GW. Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol. 2009 Sep;2(5):287-302. [CrossRef]

  • 12. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000 Apr;288(5464):339-44.

  • 13. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol. 1999 Apr;73(4):2938-46.

  • 14. Abbate I, Cappiello G, Lo Iacono O, Longo R, Ferraro D, Antonucci G, Di Marco V, Di Stefano R, Craxì A, Solmone MC, Spanò A, Ippolito G, Capobianchi MR. Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STDIFN plus RBV. J Biol Regul Homeost Agents. 2003 Apr- Jun;17(2):162-5.

  • 15. Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, Ferraro D, Antonucci G, Di Marco V, Solmone M, Craxì A, Ippolito G, Capobianchi. MR. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol. 2004 May;40(5):831-6. [CrossRef]

  • 16. López-Labrador FX, Ampurdanès S, Giménez- Barcons M, Guilera M, Costa J, Jiménez de Anta MT, Sánchez- Tapias JM, Rodés J, Sáiz JC. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. Hepatology. 1999 Mar;29(3):897-903. [CrossRef]

  • 17. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis. 2006 Apr;193(7):931-40.

  • 18. Sandres K, Dubois M, Pasquier C, Payen JL, Alric L, Duffaut M, Vinel JP, Pascal JP, Puel J, Izopet J. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol. 2000 Jan;74(2):661-8. [CrossRef]

  • 19. Torres-Puente M, Cuevas JM, Jiménez-Hernández N, Bracho MA, García-Robles I, Wrobel B, Carnicer F, Del Olmo J, Ortega E, Moya A, González-Candelas F. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Viral Hepat. 2008 Mar;15(3):188-99.

  • 20. Gerotto M, Dal Pero F, Loffreda S, Bianchi FB, Alberti A, Lenzi M. A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinemia type 2. Blood. 2001 Nov;98(9):2657-63.

  • 21. Laskus T, Radkowski M, Wang LF, Nowicki M, Rakela J. Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication. J Virol. 2000 Jan;74(2):1014-7. [CrossRef]

  • 22. Laskus T, Wilkinson J, Gallegos-Orozco JF, Radkowski M, Adair DM, Nowicki M, Operskalski E, Buskell Z, Seeff LB, Vargas H, Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology. 2004 Sep;127(3):764-76.

  • 23. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep;461(7262):399-401. [Web of Science]

  • 24. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009 Oct;41(10):1105-9. [CrossRef] [Web of Science]

  • 25. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol. 2005 Mar;79(5):3071-83. [CrossRef]

  • 26. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3081-6. [CrossRef]

  • 27. Pawlotsky JM, Germanidis G, Frainais PO, Bouvier M, Soulier A, Pellerin M, Dhumeaux D. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol. 1999 Aug;73(8):6490-9.

  • 28. Pawlotsky JM, Pellerin M, Bouvier M, Roudot- Thoraval F, Germanidis G, Bastie A, Darthuy F, Rémiré J, Soussy CJ, Dhumeaux D. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol. 1998 Apr;54(4):256-64. [CrossRef]

  • 29. Polyak SJ, McArdle S, Liu SL, Sullivan DG, Chung M, Hofgärtner WT, Carithers RL Jr, McMahon BJ, Mullins JI, Corey L, Gretch DR. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol. 1998 May;72(5):4288 96.

  • 30. Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology. 1996 Nov;24(5):1018 23. [CrossRef]

  • 31. Lange CM, Susser S, Herrmann E, Karey U, Kieffer TL, Kwong AD, Schinkel J, Reesink HW, Zeuzem S, Sarrazin C. HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a. Scand J Gastroenterol. 2011 Nov;46(11):1362-8 [CrossRef]

Comments (0)

Please log in or register to comment.